477979-20-7Relevant academic research and scientific papers
A highly efficient and enantioselective synthesis of EEHP and EMHP: intermediates of PPAR agonists
Gangar, Mukesh,Harikrishnan,Goyal, Sandeep,Mungalpara, Maulik N.,Nair, Vipin A.
, p. 3462 - 3467 (2016)
Glycolate alkylation reactions of (S)-4-isopropyl-1-[(R)-1-phenylethyl]imidazolidin-2-one auxiliary has been optimised with high yields and diastereoselectivity on substituted benzyl and allyl bromides. The standardised reaction condition was employed for the stereoselective synthesis of EEHP and EMHP intermediates of PPAR agonists.
Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists
Brenna, Elisabetta,Fuganti, Claudio,Gatti, Francesco G.,Parmeggiani, Fabio
experimental part, p. 2594 - 2599 (2010/03/30)
A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the α-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively.
An asymmetric synthesis of PPAR-γ agonist navaglitazar from (+)-methyl (2S,3R)-3-(4-methoxyphenyl)glycidate
Rizzo, John R.,Zhang, Tony Y.
, p. 580 - 583 (2007/10/03)
An asymmetric synthesis of navaglitazar, a peroxisome proliferator activated receptor (PPAR) γ agonist, from commercially available (+)-methyl (2S,3R)-3-(4-methoxyphenyl)glycidate, is described. The new synthesis features high overall yield, low solvent usage, crystalline intermediates and operational simplicity. Schweizerische Chemische Gesellschaft.
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents
Martín, José A.,Brooks, Dawn A.,Prieto, Lourdes,González, Rosario,Torrado, Alicia,Rojo, Isabel,López De Uralde, Beatriz,Lamas, Carlos,Ferritto, Rafael,Dolores Martín-Ortega, María,Agejas, Javier,Parra, Francisco,Rizzo, John R.,Rhodes, Gary A.,Robey, Roger L.,Alt, Charles A.,Wendel, Samuel R.,Zhang, Tony Y.,Reifel-Miller, Anne,Montrose-Rafizadeh, Chahrzad,Brozinick, Joseph T.,Hawkins, Eric,Misener, Elizabeth A.,Briere, Daniel A.,Ardecky, Robert,Fraser, James D.,Warshawsky, Alan M.
, p. 51 - 55 (2007/10/03)
Herein we describe a series of potent and selective PPARγ agonists with moderate PPARα affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes. Herein we describe a series of potent and selective PPARγ agonists with moderate PPARα affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes.
AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS
-
Page 27, (2010/02/05)
The present invention is directed to compounds, compositions, and use of compounds the structural Formula (I).
